scholarly journals Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Ann Rita Halvorsen ◽  
Gunnar Kristensen ◽  
Andy Embleton ◽  
Cybil Adusei ◽  
Maria Pilar Barretina-Ginesta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Response To Treatment ◽  
Rank Test ◽  
Specific Marker ◽  
High Grade ◽  
Standard Chemotherapy ◽  
Validation Set ◽  
Serous Tumors

Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included (n=207) in this study. Screening of 754 unique microRNAs was performed in the discovery phase (n=91) using TaqMan Low Density Arrays. The results were validated using single assays and RT-qPCR. Low levels of miR-200b, miR-1274A (tRNALys5), and miR-141 were significantly associated with better survival, confirmed with log-rank test in the validation set. The level of miR-1274A (tRNALys5) correlated with outcome was especially pronounced in the high-grade serous tumors. Interestingly, low level of miR-200c was associated with 5-month prolongation of PFS when treated with bevacizumab compared to standard chemotherapy. We found prognostic significance of miR-200b, miR-141, and miR-1274A (tRNALys5) in all histological types, where miR-1274A (tRNALys5) may be a specific marker in high-grade serous tumors. The level of miR-200c may be predictive of effect of treatment with bevacizumab. However, this needs further validation.

scholarly journals Asporin Is Highly Expressed in CAFs of High Grade Serous Ovarian Cancinoma Patients and Predicts Poor Prognosis

2021 ◽  
Author(s):  
Lili Wang ◽  
Xiangrong Zheng ◽  
Junhua Zhang ◽  
Wenwen Zhang ◽  
Yan Huang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Analysis ◽  
Tumor Microenvironment ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
High Grade ◽  
Clinical Value ◽  
Positive Expression

Abstract Background: Tumor microenvironment is widely considered as a critical factor influencing prognosis of ovarian cancer patients. To further improve the unsatisfied clinical outcome of ovarian cancer patients, it is desperately needed to explore biomarkers with potential clinical value of ovarian cancer. Asporin (ASPN), as a member of the proteoglycan family in tumor microenvironment, has been proved to play a vital role in cancer progression by binding with CD44 receptor. However, there is still no report about the research of Asporin in ovarian cancer. The purpose of the present study was to explore the expression and prognostic significance of Asporin in high grade serous ovarian cancinoma(HGSOC). Methods: The expression level of Asporin and CD44 in 85 formalin fixed paraffin embedded (FFPE) samples of 85 HGSOC patients was detected by immunohistochemistry. The association between the expression of the two biomarkers and the clinicopathologic factors of HGSOC was assessed by χ² test. The survival analyses were performed by Kaplan-Meier.Results: Asporin was mainly expressed in CAFs of 85 HGSOC patients, while CD44 was mainly expressed on membrane of tumor cells. The positive rates of Asporin, CD44, and Asporin /CD44 co-expression were 43.53% (37/85), 34.12% (29/85) and 28.23% (24/85) in 85 HGSOC tissues, respectively. There were close associations between Asporin, CD44, Asporin/CD44 expression and CA125 level of blood, tumor differentiation, FIGO staging, chemoresistance of HGSOC patients. Further, univariate survival analysis showed that positive expression of Asporin and positive Asporin/CD44 co-expression of HGSOC indicated poor clinical outcomes, and multivariate survival analysis suggested that positive expression of Asporin and positive Asporin/CD44 co-expression were independent prognostic factors for disease–free survival (DFS) and overall survival (OS) of HGSOC patients, respectively.Conclusion: Asporin was mainly expressed in CAFs of HGSOC patients. High expression of Asporin may identify a subgroup of HGSOC patients with more chemoresistance clinicopathological features and may be a potential prognostic predictor and therapeutic target for HGSOC patients.

Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients

2021 ◽  
Author(s):  
Anna P. Sokolenko ◽  
Tatiana V. Gorodnova ◽  
Ilya V. Bizin ◽  
Ekaterina Sh. Kuligina ◽  
Khristina B. Kotiv ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

2014 ◽  
Vol 9 (2) ◽  
pp. 422-436 ◽  
Author(s):  
Marta M. Kamieniak ◽  
Daniel Rico ◽  
Roger L. Milne ◽  
Ivan Muñoz-Repeto ◽  
Kristina Ibáñez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
High Grade ◽  
Serous Epithelial Ovarian Cancer

scholarly journals SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery

2020 ◽  
Vol 7 (6) ◽  
pp. 1805094
Author(s):  
Maria Bååth ◽  
Sofia Westbom-Fremer ◽  
Laura Martin de la Fuente ◽  
Anna Ebbesson ◽  
Juliette Davis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Residual Disease ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer ◽  
Debulking Surgery

Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer

2017 ◽  
Vol 42 (10) ◽  
pp. 2513-2520 ◽  
Author(s):  
L. J. McIntosh ◽  
A. C. O’Neill ◽  
S. Bhanusupriya ◽  
S. A. Matalon ◽  
A. D. Van den Abbeele ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Nodes ◽  
Prognostic Significance ◽  
Initial Presentation ◽  
Stage Iii ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?

2019 ◽  
Vol 154 (1) ◽  
pp. 138-143 ◽  
Author(s):  
Federica Tomao ◽  
Lucia Musacchio ◽  
Federica Di Mauro ◽  
Serena Maria Boccia ◽  
Violante Di Donato ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Hematologic Toxicity ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Mutational Status ◽  
Platinum Based Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document